NEW YORK (TheStreet) -- CHANGE IN RATINGS
Adobe was upgraded at FBR Capital Markets to market perform from underperform. Negative catalysts have already played out, FBR Capital Markets said.
BorgWarner was upgraded at Robert Baird to outperform from neutral. $107 price target. Earnings growth is set to accelerate, Baird said.
BRT Realty Trust was upgraded to hold at TheStreet Ratings.
FMC Technologies was downgraded at Bank of America/Merrill Lynch to neutral from buy. Price target is $62. Slowing growth and the potential loss of the Block 32 project could hurt future earnings, BofA/Merrill Lynch said.
Hologic was downgraded at Piper Jaffray to neutral from overweight. Legacy mammography business should be a drag on growth, Piper Jaffray said. $21 price target.
Iteris was upgraded to buy at TheStreet Ratings.
Johnson & Johnson was downgraded at Deutsche Bank to neutral from buy. Price target is $93. Major catalysts and improving fundamentals have been priced into the stock, Deutsche Bank said.
Medivation was upgraded at UBS to buy from neutral and given a $74 price target, said UBS. The upgrade comes ahead of the ph3 PREVAIL study, UBS said.
Packaging Corp. was downgraded at BMO Capital to market perform from outperform. Price target was increased to $55. Stock is trading at a premium to its seven-year average and the majority of its competition, BMO Capital said.
Scripps was downgraded at Wunderlich to hold from buy. Valuation call, based on a $77 price target, Wunderlich said.
Time Warner Telecom was downgraded at Deutsche Bank to hold from buy. Valuation call, Deutsche Bank said.
STOCK COMMENTS/EPS CHANGES
Comerica numbers were raised at BMO Capital Markets. Shares are now seen reaching $41. Estimates were also increased on the beat in the second quarter of 2013 as well as lower provision expense, BMO Capital Markets said.
Comerica estimates, price target were upped at Jefferies. Estimates were raised through 2014. Company is seeing lower provision expenses, Jefferies said. Hold rating and new $42 price target.
Salesforce.com estimates were reduced at Citigroup. Reflects the ExactTarget acquisition, said Citigroup.
Gilead estimates, price target were increased at Oppenheimer. Estimates were raised through 2014. Company can gain market share in Genotype 1 HCV, Oppenheimer said. Outperform rating and new $63 price target.
Goldman Sachs numbers raised at UBS. Earnings estimates were raised given better revenue outlook and buybacks, said UBS. Price target goes to $165.
Johnson & Johnson numbers were boosted at Jefferies. Shares are now seen reaching $95. Estimates also upped, given better pharmaceuticals growth, Jefferies said. Hold rating.
Starbucks price target was raised at Oppenheimer. Shares are now seen reaching $75. Company can continue to deliver strong sales and expand margins, Oppenheimer said. Outperform rating.
Charles Schwab numbers were raised at UBS. Earnings estimates were raised given NIM upside, said UBS. Price target goes to $21.
>To submit a news tip, email: firstname.lastname@example.org.